The global fill-finish manufacturing market size is projected to grow from USD 7.5 billion in 2020 to USD 14.2 billion by 2027, at a CAGR of 9.5 % during the forecast period.Fill finish manufacturing is a process of filling biologics in an aseptic condition. Biologics are filled in different products of containers like vials, bottles, syringes, cartridges, ampoules, bags, etc. It is a crucial step in the manufacturing of pharmaceutical products after downstream processes, filtration, and up-stream cell culture.
The spike in demand for pharmaceutical products is one of the biggest drivers for the global fill finish market. In many cases, the same drug is manufactured in multiple forms to suit the requirement of the patients. This is another factor fueling growth in the global fill finish manufacturing market.
Further, development in healthcare is a major contributing factor to the global fill finish manufacturing market. The total number of people requiring healthcare and medical attention has grown in the last few years. This shoots up the consumption of medications, propelling the global fill finish market.
Another important driver is the increasing thrust on scientific research. Governments and private organizations has pumped more funds to support research for niche healthcare products. Research requires biologics in purest forms, and this is a significant aspect for the global fill finish manufacturing market.
Despite the large number of drivers, the global fill finish manufacturing market faces some restraints. High cost involved in some processes along with difficulties in manufacturing certain products of products is some challenges. Nevertheless, research is on to identify innovative techniques to simplify this process and reduce investment.
The major companies in the fill-finish manufacturing market include Becton, Dickson and Company (US), Syntegon Technology GmbH (Germany), I.M.A. (IndustriaMacchineAutomatiche) S.p.A. (Italy), Stevanato Group (Italy), West Pharmaceutical Services, Inc. (US), OPTIMA Packaging Group GmbH (Germany), Bausch+Strobel (Germany), Groninger& Co. GmbH (Germany), and Gerresheimer AG (Germany).
Europe accounted for the largest share of the global market, closely followed by North America. Factors such as the emergence of the bio-similar market due to the patent expiry of key biologic products, rising incidence of chronic disorders, and the increasing focus of major players on increasing their presence in this region are driving the growth of the fill-finish manufacturing industry in Europe.
The Asia Pacific region is expected to witness the highest CAGR during the forecast period, mainly due to overall growth in the biopharmaceutical industry. The growth of the APAC biopharmaceutical market is attributed to factors, such as increasing investments by CMOs & key biopharmaceutical players, increasing government support, developments in R&D infrastructure, and expertise & academic excellence in the APAC region.